Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic LeukemiaMichael J. Keating, Hagop M. Kantarjian, Susan O’Brien et al.|Journal of Clinical Oncology|2005Cited by 951
Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop M. Kantarjian, Susan O’Brien, Anjali S. Advani et al.|The Lancet Oncology|2012Cited by 411
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adultsNitin Jain, Marina Konopleva, Kathryn G. Roberts et al.|Blood|2016Cited by 385
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemiaHagop M. Kantarjian, Susan O’Brien, Deborah A. Thomas et al.|Cancer|2013Cited by 302
Mylotarg? (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantationFrancis J. Giles, Elihu H. Estey, H. Kantarjian et al.|Cancer|2001Cited by 280